Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Interferon-alpha (IFN-alpha) is used in cancer therapy.
• Monocytes play a crucial role in the immune response through phagocytosis.
• Natural killer (NK) cells are important for innate immunity against tumors.

Purpose of the Study:

• To investigate the effect of daily IFN-alpha injections on peripheral monocyte phagocytic activity in cancer patients.
• To explore the relationship between changes in monocyte phagocytosis and NK cell activity during IFN-alpha therapy.

Main Methods:

• 28 tumor patients received daily intramuscular injections of 3 X 10(6) units of IFN-alpha.
• Monocyte phagocytic activity was assessed by their capacity to ingest yeast particles.
• Natural killer (NK) cell activity was measured concurrently in some patients.

Main Results:

• No significant change in monocyte phagocytosis was observed one day after initiating IFN-alpha therapy.
• A progressive decrease in monocyte phagocytic activity was noted in most patients after 1 week, 3 months, 6 months, and 9 months of treatment.
• A correlation was found between increased NK cell activity and decreased monocyte phagocytosis.

Conclusions:

• Long-term administration of IFN-alpha may suppress the phagocytic function of monocytes in cancer patients.
• The observed inverse correlation suggests a potential immunomodulatory interplay between NK cells and monocytes under IFN-alpha treatment.
• Further research is warranted to understand the clinical implications of these immune system alterations.